160 related articles for article (PubMed ID: 11652031)
41. Biologists in pinstripes.
Pollack R
Sciences (New York); 1982 Oct; 22(7):35-7. PubMed ID: 11650586
[No Abstract] [Full Text] [Related]
42. Patient-funded research: paying the piper or protecting the patient?
Morreim EH
IRB; 1991; 13(3):1-6. PubMed ID: 11651046
[No Abstract] [Full Text] [Related]
43. Competing interests: the need to control conflict of interests in biomedical research.
Steiner D
Sci Eng Ethics; 1996 Oct; 2(4):457-68. PubMed ID: 11657732
[No Abstract] [Full Text] [Related]
44. Drug trials hide conflicts for doctors.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():1, 34. PubMed ID: 11648114
[No Abstract] [Full Text] [Related]
45. Pajaro Dunes Conference: draft statement.
Pajaro Dunes Conference
J Coll Univ Law; 1982-1983; 9(4):533-9. PubMed ID: 11650709
[No Abstract] [Full Text] [Related]
46. Biotechnology and open university science.
Grobstein C
Sci Technol Human Values; 1985; 10(2):55-63. PubMed ID: 11649681
[No Abstract] [Full Text] [Related]
47. Patient care vs. corporate connections: Cleveland Clinic wants to change but won't cut ties to industry.
Abelson R; Pollack A
N Y Times Web; 2005 Jan; ():C1, C4. PubMed ID: 15682548
[No Abstract] [Full Text] [Related]
48. Commentary: biology faces life--pressures on communications and careers.
Holtzman E
Sci Technol Human Values; 1985; 10(2):64-72. PubMed ID: 11649682
[No Abstract] [Full Text] [Related]
49. Research as intellectual property: influences within the university.
Rosenzweig RM; Bremer HW
Sci Technol Human Values; 1985; 10(2):41-54. PubMed ID: 11649680
[No Abstract] [Full Text] [Related]
50. A doctor's drug studies turn into fraud.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():A1, A16. PubMed ID: 11647660
[No Abstract] [Full Text] [Related]
51. Drug firm, relenting, allows unflattering study to appear.
Altman LK
N Y Times Web; 1997 Apr; ():A1, A16. PubMed ID: 11647207
[No Abstract] [Full Text] [Related]
52. Biotechnology and the commercial use of human cells: toward an organic view of life and technology.
Martin PA; Lagod ML
Santa Clara Comput High Technol Law J; 1989 Jun; 5(2):211-61. PubMed ID: 11659674
[No Abstract] [Full Text] [Related]
53. Conflict or synergy: university-industry research relations.
Schmitt RW
Account Res; 1997; 5(4):251-4. PubMed ID: 11656991
[No Abstract] [Full Text] [Related]
54. When physicians double as entrepreneurs. Hidden interests: a special report.
Eichenwald K; Kolata G
N Y Times Web; 1999 Nov; ():A1, C16-17. PubMed ID: 11648142
[No Abstract] [Full Text] [Related]
55. Editorial ethics questioned.
Vogel G
Science; 1997 Feb; 275(5303):1055. PubMed ID: 11644901
[No Abstract] [Full Text] [Related]
56. Splice Einstein and Sammy Glick, add a little Magellan: banking on genes.
Belkin L
N Y Times Mag; 1998 Aug; ():26-31, 56, 58,. PubMed ID: 11648100
[No Abstract] [Full Text] [Related]
57. Sponsors lose fight to stop thyroxine study publication.
McCarthy M
Lancet; 1997 Apr; 349(9059):1149. PubMed ID: 11654726
[No Abstract] [Full Text] [Related]
58. Industry funds in universities: new guidelines emerge from Pajaro Dunes.
Dickson D
Nature; 1982 Apr; 296(5856):381-2. PubMed ID: 11643726
[TBL] [Abstract][Full Text] [Related]
59. Academe and industry debate partnership.
Culliton BJ
Science; 1983 Jan; 219(4581):150-1. PubMed ID: 11643998
[TBL] [Abstract][Full Text] [Related]
60. Proprietary rights and the norms of science in biotechnology research.
Eisenberg RS
Yale Law J; 1987 Dec; 97(2):177-231. PubMed ID: 11660398
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
